Corbus Pharmaceuticals Receives FDA Fast Track Designation

An update from Corbus Pharmaceuticals ( (CRBP) ) is now available.

Corbus Pharmaceuticals reported its second quarter 2025 financial results, highlighting a net loss of $17.7 million, an increase from the previous year due to higher clinical development expenses. The company is advancing its clinical programs with data readouts expected in the second half of 2025. Notably, CRB-701, targeting Nectin-4 in solid tumors, received FDA Fast Track designation for metastatic cervical cancer. The company also initiated a Phase 1 study for its obesity drug, CRB-913, and plans to present data at the ESMO Congress in October 2025.

The most recent analyst rating on (CRBP) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.

Spark’s Take on CRBP Stock

According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.

Corbus Pharmaceuticals’ overall stock score is driven by severe financial challenges, including no recent revenue and high net losses, which significantly weigh down its score. However, technical indicators suggest some short-term positive momentum. The promising Phase 1 trial results provide a potential catalyst in the biotechnology field, offering some positive outlook despite the current financial difficulties.

To see Spark’s full report on CRBP stock, click here.

More about Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage company focused on oncology and obesity treatments. The company is dedicated to innovative scientific approaches targeting well-understood biological pathways. Its pipeline includes CRB-701, an antibody drug conjugate targeting Nectin-4 on cancer cells, CRB-601, an anti-integrin monoclonal antibody for solid tumors, and CRB-913, a CB1 receptor inverse agonist for obesity treatment. Corbus is headquartered in Norwood, Massachusetts.

Average Trading Volume: 155,887

Technical Sentiment Signal: Sell

Current Market Cap: $113.9M

For an in-depth examination of CRBP stock, go to TipRanks’ Overview page.